Another piece of the digital health and wellness puzzle

By Trevor Hoey. Published at Aug 12, 2016, in Features

ImpediMed (ASX:IPD) announced on Thursday that its new SOZO product is available for global pre-order. The product allows consumers and patients to measure and track their body composition, fluid status and hydration in a variety of settings.

In terms of its overall operations, Brisbane based ImpediMed is a leading player in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients.

The company has the first medical device with FDA clearance in the US to aid healthcare professionals in clinically assessing secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

With regards to the SOZO product it is an intuitive digital health device and wellness platform that combines BIS technology with artificial intelligence to create a rapid, non-invasive scan of a person’s body providing a precise and repeatable snapshot of a person’s body composition, fluid status and hydration.

Predictive analytics in SOZO can access cloud-based historical health data in order to create customised plans for user’s personal health and wellness goals. The technology is compatible with iOS and android devices.

At a time when wearable devices that measure physical performance are coming under the spotlight, it could be a stock to watch. One only has to look at the success of Catapult Group International (CAT) to see the success that these stocks are having. Its shares have increased three-fold in the last 12 months from circa $1.30 to yesterday’s close of $3.94.

ImpediMed has also had a good run with its share price more than doubling from 77 cents in April to hit an intraday high of $1.71 yesterday.

The share price performances of ImpediMed or Catapult Group should not be used as a guide to future performance or be used to as a basis for an investment decision.

Scott Power from Morgans CIMB likes the stock and on Friday morning he increased his target price from $1.97 to $2.13, implying a premium of 25% to yesterday’s closing price of $1.70.

However, it should be noted that broker projections and price targets are only estimates and any investment decision should not be based solely on this information.

Power is forecasting ImpediMed to deliver a maiden profit of $16.4 million in fiscal 2018, representing earnings per share of 4.4 cents. He said his investment view remained positive and expects upcoming news flow will move the share price higher.

This should include regular updates on US L-Dex adoption and sales, as well as progress on inclusion of lymphoedema in additional cancer guidelines.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn